Enlight Biosciences Forms Lucrative New Partnerships

Enlight Biosciences LLC recently announced today it has formed new partnerships with AstraZeneca and Novo Nordisk. As partners in Enlight, AstraZeneca and Novo Nordisk will have the opportunity to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight was created by PureTech Ventures in partnership with major pharmaceutical companies and academic luminaries to proactively address critical unmet industry needs.

“One of the keys to the success of Enlight is the rich dialogue between our network of scientific and clinical experts together with our pharmaceutical partners,” said Enlight’s CEO Michelle Browner, PhD. “We will greatly benefit from contributions of AstraZeneca and Novo Nordisk to this excellent group of industry and academic leaders.”

“This partnership reflects AstraZeneca’s commitment to accessing and fostering innovation that exists outside of our own labs,” added Menelas Pangalos, Executive Vice President, Innovative Medicines, AstraZeneca. “Enlight provides a unique opportunity for AstraZeneca and MedImmune, our biologics arm, to collaborate with our peers and contribute to the development of tools that will fundamentally enhance R&D across the industry.”

“At Novo Nordisk, we apply our unique combination of skills in protein engineering and expression, formulation, and delivery to enhance the quality of care and bring new treatment options to patients,” said Mads Krogsgaard Thomsen, Executive Vice President and CSO at Novo Nordisk. “Through our participation in Enlight, we will be able to actively support the advancement of innovative ideas while proactively addressing the needs of our expanding global R&D organization.”

Enlight’s innovations are drawn from academic laboratories, start-ups, and ideas generated internally by the Enlight team, including a scientific advisory board led by Nobel Laureate Dr. H. Robert Horvitz. Enlight is focused on areas that include molecular imaging, biologics, and drug formulation and delivery methods, as well as novel chemistries and production technologies, biomarkers, and drug safety. Hundreds of technology opportunities are evaluated each year, with only the top one or two selected to become actively managed programs.

Since its founding in 2008, Enlight has publicly announced the formation of two companies Entrega and Endra and in addition, has several companies that have not yet been publically announced. Entrega is developing a proprietary delivery technology to enable the oral administration of proteins, peptides, and difficult-to-deliver small molecules. Endra has commercialized a breakthrough preclinical imaging technology that combines the properties of lightbased (optical) imaging with ultrasound to enable advanced live-animal imaging for preclinical research.